Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2

Leukemia and Lymphoma

Volumn 54, Issue 3, 2013, Pages 569-578

  Eadie, Laura N ^a,b,c   Saunders, Verity A ^a,c   Hughes, Timothy P ^a,b,c   White, Deborah L ^a,b,c  

^a Rundle Mall   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c CENTRE FOR CANCER BIOLOGY   (Australia)

Author keywords

ABC transporters; CML; Imatinib; Nilotinib

Indexed keywords

BCR ABL PROTEIN; BREAST CANCER RESISTANCE PROTEIN; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; NILOTINIB;

ARTICLE; CELL STRAIN K 562; CONCENTRATION (PARAMETERS); ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; INTRACELLULAR TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT;

ADENOSINE; ATP-BINDING CASSETTE TRANSPORTERS; BENZAMIDES; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; CYCLOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 84873362373     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.715345     Document Type: Article

References (45)

1. Rees DC, Johnson E, Lewinson O. ABC transporters: the power to change. Nat Rev Mol Cell Biol 2009;10: 218-227.
2. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101: 2368-2373.
3. Nakanishi T, Shiozawa K, Hassel BA, et al. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction ofBCRP expression. Blood 2006;108: 678-684.
4. Widmer N, Colombo S, Buclin T, et al. Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood 2003;102: 1142.
5. Brendel C, Scharenberg C, Dohse M, et al. Imatinib mesylate and nilotinib (AMN107) exhibit high-af nity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007: 21: 1267-1275.
6. Burger H, van Tol H, Boersma AW, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drugpump. Blood 2004;104: 2940-2942.
7. Dai H, Marbach P, Lemaire M, et al. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated eflux. J Pharmacol Exp Ter 2003;304: 1085-1092.
8. Hegedus T, Orf L, Seprodi A, et al. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 2002;1587: 318-325.
9. Dohse M, Scharenberg C, Shukla S, et al. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 2010;38: 1371-1380.
10. Davies A, Jordanides NE, Giannoudis A, et al. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or eflux by major drug transporters. Leukemia 2009;23: 1999-2006.
11. Hegedus C, Ozvegy-Laczka C, Apati A, et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer Effects and pharmacological properties. Br J Pharmacol 2009;158: 1153-1164.
12. Houghton PJ, Germain GS, Harwood FC, et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004: 64: 2333-2337.
13. Jordanides NE, Jorgensen HG, Holyoake TL, et al. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited byimatinib mesylate. Blood 2006;108: 1370-1373.
14. Liu W, Baer MR, Bowman MJ, et al. The tyrosine kinase inhibitor imatinib mesylate enhances the ef cacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res 2007;13: 2463-2470.
15. Tiwari AK, Sodani K, Wang SR, et al. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol 2009;78: 153-161.
16. Szakacs G, Varadi A, Ozvegy-Laczka C, et al. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 2008;13: 379-393.
17. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an ef cient Hoechst 33342 eflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002;99: 507-512.
18. Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001: 7: 1028-1034.
19. Blume H, Donath F, Warnke A, et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006: 29: 769-784.
20. Breedveld P, Zelcer N, Pluim D, et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004: 64: 5804-5811.
21. Pauli-Magnus C, Murdter T, Godel A, et al. P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn Schmiedebergs Arch Pharmacol 2001;363: 337-343.
22. Shi Z, Tiwari AK, Shukla S, et al. Sildenaf l reverses ABCB1-and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res 2011;71: 3029-3041.
23. Suzuki K, Doki K, Homma M, et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 2009;67: 44-49.
24. White D, Saunders V, Lyons AB, et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005;106: 2520-2526.
25. White DL, Saunders VA, Dang P, et al. OCT-1-mediatedinf ux is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108: 697-704.
26. Ozvegy C, Litman T, Szakacs G, et al. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 2001: 285: 111-117.
27. Raaijmakers MH, de Grouw EP, van der Reijden BA, et al. ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia. Clin Cancer Res 2006: 12: 3452-3458.
28. Crossman LC, Druker BJ, Deininger MW, et al. hOCT 1 and resistance to imatinib. Blood 2005;106: 1133-1134: author reply 1134.
29. Tomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004: 104: 3739-3745.
30. Tanaka C, Yin OQ, Sethuraman V, et al. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ter 2010;87: 197-203.
31. O'Hare T, Walters DK, Stofregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65: 4500-4505.
32. Hughes T, Saglio G, Branford S, et al. Impact ofbaseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009;27: 4204-4210.
33. Burger H, van Tol H, Brok M, et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ter 2005;4: 747-752.
34. Hirayama C, Watanabe H, Nakashima R, et al. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells. Pharm Res 2008;25: 827-835.
35. Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug eflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004;18: 401-408.
36. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with Differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms ofresistance. Blood 2000;96: 1070-1079.
37. Breedveld P, Pluim D, Cipriani G, et al. The Effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in pat ie nts. Cancer Res 2005: 65: 2577-2582.
38. Mahon FX, Hayette S, Lagarde V, et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 2008: 68: 9809-9816.
39. Dohse M, Scharenberg C, Shukla S, et al. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 2010: 38: 1371-1380.
40. Ozvegy-Laczka C, Hegedus T, Varady G, et al. High-af nity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004;65: 1485-1495.
41. Hiwase DK, White D, Zrim S, et al. Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. Leukemia 2010: 24: 658-660.
42. Hazarika M, Jiang X, Liu Q, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 2008: 14: 5325-5331.
43. Kerns EH, Di L. Drug-like properties: concepts, structure design and methods: from ADME to toxicity optimization. Amsterdam: Academic Press: 2008.
44. White D, Dang P, Venables A, et al. ABCB1 overexpression may predispose imatinib treated CML patients to the development of Abl kinase domain mutations, and may be an important contributor to acquired resistance. Blood 2006: 108(Suppl. 1): Abstract 2144.
45. Tang C, Schafranek L, Watkins DB, et al. Tyrosinekinaseinhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. Leuk Lymphoma 2011: 52: 2139-2147.